P/B
1,2
BioNTech
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
$24.4B
Market Cap • 10/9/2026
2008
(18 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
Germany
Country
Valuation
P/S
7,5
P/EBITDA
—
P/OCF
30,3
P/FCF
43,5
P/E
—
BVPS
80,7
EPS
—
Market Cap
Market Cap
24,4B
EV
7,9B
EV/Revenue
2,4
EV/EBITDA
-5,2
EV/EBIT
-3,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,6%
Total Yield
0,6%
Dividend Yield 5Y
0%
Payout
0%
Retained Earnings
19B
Profitability
Gross Margin
76,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
77,8%
Capex/Revenue
7,5%
Capex/D&A
31,2%
Capex/OCF
30,4%
SBC/OCF
13,8%
% PPE
6%
% Goodwill
1,8%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
10,9
Debt/Equity
0%
Current Ratio
7,8
Quick Ratio
7,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!